Clinical trials: Hospitalized COVID-19
COVID-19
Predicting COVID-19 Patients' Clinical Outcomes Using ICU Mobility Scale and MRC Sum Score
The investigators hypothesize that early mobility condition and muscle power may be the predictive factors for Coronavirus disease 2019(COVID-19) patients' activity prognosis and hospitalization days.
- Trial name
- NCT05195736
- Where
- Taiwan
- Volunteers
- 33 people
- Sponsor
- Taichung Veterans General Hospital
COVID-19
COVID-19 Clinical Status Associated With Outcome Severity: An Unsupervised Machine Learning Approach
Since the beginning of the COVID-19 pandemic, 195 million people have been infected and 4.2 million have died from the disease or its side-effects.
- Trial name
- NCT05119465
- Where
- Greece
- Volunteers
- 268 people
- Sponsor
- Aristotle University Of Thessaloniki
COVID-19 Infection, Parathyroid Gland
The Status of Parathyroid Hormone Secretion in Covid-19 Patients
COVID-19 infection causes a hypersensitive immune reaction and widespread inflammation in various organs of the body, especially through cytokines in the lungs.
- Conditions
- COVID-19 Infection, Parathyroid Gland, Parathyroid Hormone, Calcium
- Trial name
- NCT04662437
- Testing
- Venous blood was collected for biochemistry testing
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bezmialem Vakif University
SARS Virus
IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.
High-throughput screening studies identified Abl kinase inhibitors (including imatinib) as inhibitors of coronaviruses SARS and MERS. The SARS-CoV-2 coronavirus depend on Abl2 kinase activity to fuse and enter into the cells.
- Trial name
- IMAGE-19 (NCT04357613)
- Testing
- Experimental drug
- Where
- 2 sites in France
- Volunteers
- 99 people
- Sponsor
- Versailles Hospital
COVID, Vitamin D Deficiency
The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations
Although the novel SARS-CoV-2 virus (COVD-19) is classified as an acute respiratory infection, emerging data show that morbidity and mortality are driven by disseminated intravascular coagulopathy.
- Conditions
- COVID, Vitamin D Deficiency, Coagulopathy, Disseminated Intravascular Coagulation
- Trial name
- LEAD COVID-19 (NCT04363840)
- Testing
- Aspirin 81 mg, Vitamin D
- Sponsor
- Louisiana State University Health Sciences Center in New Orleans
COVID-19
Impact of COVID-19 Outbreak on Non-COVID-19 Patients
The Geneva Canton organized the health crisis of the COVID-19 epidemic around the care of COVID patients at the University Hospital (HUG), by moving the care of non-COVID patients to private hospitals of the canton.
- Trial name
- NoCOVImpact (NCT04537559)
- Where
- Switzerland
- Volunteers
- 240,000 people
- Sponsor
- University Hospital, Geneva
Coronavirus Infections, Diabetes Mellitus
Covid-19 and Diabetes in West of Algeria
By Jan 7, 2020, Chinese scientists had isolated a novel coronavirus, from patients with virus-infected pneumonia. The WHO designated later this virus as COVID-19 (coronavirus disease 2019).
- Conditions
- Coronavirus Infections, Diabetes Mellitus, Prevalence, Risk Factors
- Trial name
- COVIDIAB-13 (NCT04412746)
- Testing
- MANAGEMENT OF COVID-19
- Where
- Algeria
- Volunteers
- 100 people
- Sponsor
- Laboratoire De Recherche Sur Le Diabete, Université de Tlemcen
COVID-19 Infection
Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection
Treatment of patients hospitalised for management of moderate COVID-19 infection
- Trial name
- Neptuno (NCT04784559)
- Testing
- Plitidepsin, Dexamethasone, Remdesivir
- Where
- 28 sites in Brazil, Bulgaria and 6 more
- Volunteers
- 205 people
- Sponsor
- PharmaMar
Covid19
RCT,Double Blind, Placebo to Evaluate the Effect of Zinc and Ascorbic Acid Supplementation in COVID-19 Positive Hospitalized Patients in BSMMU
The first COVID-19 case was identified on March 7, 2020. Since then, 4127 deaths of the total 3,40583 confirmed cases are reported in Bangladesh of August 26, 2020.
- Trial name
- NCT04558424
- Testing
- zinc gluconate and ascorbic acid
- Where
- Bangladesh
- Volunteers
- 50 people
- Sponsor
- Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
COVID
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome
COVID-19 is a respiratory disease due to a novel coronavirus (SARS-CoV-2) that causes substantial morbidity and mortality. To date, no treatment has been proved to be effective in COVID-19.
- Trial name
- OUTCOV (NCT04365582)
- Testing
- Azithromycin, Hydroxychloroquine, Lopinavir 200Mg/Ritonavir 50Mg Tab
- Sponsor
- Fondation Hôpital Saint-Joseph
COVID-19
Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients
A total of 278 patients are planned. All patients will be in an early-stage of COVID-19. They must be adults and hospitalized. In this study, all participating patients will receive the standard treatment provided according to…
- Trial name
- ConPlas-19 (NCT04345523)
- Testing
- Blood and derivatives., Standard of Care
- Where
- 29 sites in Spain
- Volunteers
- 350 people
- Sponsor
- Cristina Avendaño Solá
Covid19 Immunology
The COVID-19 PUI Reality Check (CPRC) Study
This study compares SARS-CoV-2 immune responses in high pretest probability swab negative hospitalized PUI patients vs. low pretest probability swab negative hospitalized APS (Asymptomatic Persons being Screened) patients to try…
- Trial name
- CPRC (NCT04474288)
- Testing
- SARS-CoV-2 antibody testing
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Bassett Healthcare
Mild-to-moderate COVID-19
A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19
This randomized, open-label, prospective, parallel-group controlled clinical study that aims to explore the natural history of COVID-19 illness and the safety of KB109, a novel glycan, plus SSC versus SSC alone and measures of…
- Trial name
- NCT04414124
- Testing
- KB109 + Self Supportive Care (SSC), Self Supportive Care (SSC) Alone
- Where
- 16 sites in United States
- Volunteers
- 350 people
- Sponsor
- Kaleido Biosciences
COVID-19
StEroids in hospitaLized patiEnts With Covid-19 in The Netherlands.
Rationale: In patients with COVID-19 admitted to the hospital, large heterogeneity exists in patients, timing and dosing of steroid therapy. It is unclear how to treat patients who fail dexamethasone therapy.
- Trial name
- SELECT (NCT05403359)
- Testing
- Steroids
- Where
- Netherlands
- Volunteers
- 2,465 people
- Sponsor
- Henrik Endeman
Covid19, Coronavirus Disease 2019
SOLIDARITY Finland Plus Long-COVID
The SOLIDARITY PLUS Finland Long-COVID trial aims to assess the long-term effects of imatinib and infliximab, used during acute hospitalization due to COVID-19-infection, on long-COVID symptoms and quality of life (QoL) using…
- Conditions
- Covid19, Coronavirus Disease 2019, SARS-CoV-2 Acute Respiratory Disease
- Trial name
- NCT05220280
- Testing
- Imatinib, Infliximab
- Where
- Finland
- Volunteers
- 400 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
COVID-19
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
This study will measure the effect of FSD201 (ultramicronized PEA) + SoC vs placebo + SoC on Day 28, on disease progression in the confirmed coronavirus disease 2019 (COVID-19) patient population.
- Trial name
- NCT04619706
- Testing
- FSD201, Standard of Care for Covid-19
- Where
- 10 sites in United States
- Volunteers
- 53 people
- Sponsor
- Quantum Biopharma
COVID-19 Pulmonary Complications, COVID-19
Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants
The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019…
- Trial name
- NCT04382586
- Testing
- Zanubrutinib, Supportive Care
- Where
- 10 sites in United States
- Volunteers
- 63 people
- Sponsor
- BeiGene
Covid19
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19
The study is a phase II, randomized, 2-arm parallel-group, double-blind study to explore the efficacy, safety, tolerability and pharmacokinetics of KAND567 versus placebo in COVID-19 subjects in need of oxygen treatment.
- Trial name
- NCT06012565
- Testing
- KAND567, Microcrystalline cellulose
- Where
- 4 sites in Denmark, Sweden
- Volunteers
- 35 people
- Sponsor
- Novakand Pharma AB
Covid19
An Observational Cohort Trial of Outcomes and Antibody Responses Following Treatment With COVID19 Convalescent Plasma in Hospitalized COVID-19 Patients
This is an observational study designed to learn more about how COVID19 convalescent plasma works in patients with COVID19 compared to those patients who did not receive convalescent plasma treatment.
- Trial name
- NCT04471051
- Where
- 6 sites in United States
- Volunteers
- 255 people
- Sponsor
- University of Colorado, Denver
Coronavirus Infection
HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection
COVID-19 pandemic has developed worldwide in less than 4 months. The clinical presentations are variable widely, ranging from simple rhinitis to major lung damage that can lead to death.
- Trial name
- HOME-CoV (NCT04338841)
- Testing
- HOME-CoV rule implementation
- Where
- 29 sites in Belgium, France and 1 more
- Volunteers
- 3,133 people
- Sponsor
- University Hospital, Angers